Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1183/09031936.00113011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacological Strategies for High-Output Ileostomies in Children: A Narrative Review.
Acta Paediatr
January 2025
Department of Paediatric Gastroenterology, University Hospitals Leuven, Leuven, Belgium.
Aim: Nutritional measures often suffice for managing high-output ileostomy (HOI) in paediatric patients, but pharmacological treatment may be required to control ostomy output. This paper reviews the literature on the pharmacological management of paediatric HOI and provides recommendations.
Methods: PubMed and Embase were searched for relevant articles up to 22 May 2024.
Conservative management of large-volume chylous ascites following a robotic-assisted left radical nephrectomy.
BMJ Case Rep
January 2025
Urology, East Sussex Healthcare NHS Trust, Eastbourne, UK.
Chyle leak is a rare complication following nephrectomy and may result in chylous ascites. A patient in her 70s was diagnosed with a left renal tumour and underwent a robotic-assisted radical nephrectomy. She presented 9 days post discharge with chyle leaking from the left port site wound, which settled after 2 days of inpatient monitoring.
View Article and Find Full Text PDFPET imaging of Mn labeled DOTATATE and DOTAJR11.
Sci Rep
January 2025
Department of Radiology, The University of Alabama at Birmingham, Birmingham, USA.
Manganese-52 is gaining interest as an isotope for PET imaging due to its desirable decay and chemical properties for radiopharmaceutical development. Somatostatin receptor 2 (SSTR2) is significantly overexpressed by neuroendocrine tumors (NETs) and is an important target for nuclear imaging and therapy. As an agonist, [Ga]Ga-DOTATATE has demonstrated significant internalization upon interaction with receptor ligands, whereas [Ga]Ga-DOTA-JR11(as an antagonist) exhibits limited internalization but better pharmacokinetics and increased tumor uptake.
View Article and Find Full Text PDFVariations in Octreotide Dosing in Published Reports of Sulfonylurea Toxicity: A Systematic Review, 1988-Present.
J Med Toxicol
January 2025
Office of Medical Toxicology, University of Alabama Birmingham, Birmingham, USA.
Background: Octreotide is commonly used to treat hypoglycemia due to sulfonylurea toxicity, but optimal dosing for this indication is not well defined.
Methods: We performed a systematic review to identify cases in the medical literature of octreotide use for sulfonylurea poisoning. Literature published on octreotide and sulfonylureas between octreotide's FDA approval on 10/21/1988 and 8/15/2024 was reviewed.
Involvement of ATF6 in Octreotide-Induced Endothelial Barrier Enhancement.
Pharmaceuticals (Basel)
November 2024
School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, LA 71201, USA.
: Endothelial hyperpermeability is the hallmark of severe disease, including sepsis and acute respiratory syndrome (ARDS). The development of medical countermeasures to treat the corresponding illness is of utmost importance. Synthetic somatostatin analogs (SSA) are FDA-approved drugs prescribed in patients with neuroendocrine tumors, and they act via growth hormone (GH) suppression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!